Search Results - "Sperr, W R"

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site by Hadzijusufovic, E, Albrecht-Schgoer, K, Huber, K, Hoermann, G, Grebien, F, Eisenwort, G, Schgoer, W, Herndlhofer, S, Kaun, C, Theurl, M, Sperr, W R, Rix, U, Sadovnik, I, Jilma, B, Schernthaner, G H, Wojta, J, Wolf, D, Superti-Furga, G, Kirchmair, R, Valent, P

“…The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has…”
Get full text

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal by Valent, P., Sotlar, K., Sperr, W.R., Escribano, L., Yavuz, S., Reiter, A., George, T.I., Kluin-Nelemans, H.C., Hermine, O., Butterfield, J.H., Hägglund, H., Ustun, C., Hornick, J.L., Triggiani, M., Radia, D., Akin, C., Hartmann, K., Gotlib, J., Schwartz, L.B., Verstovsek, S., Orfao, A., Metcalfe, D.D., Arock, M., Horny, H.-P.

“…Mast cell leukemia (MCL), the leukemic manifestation of systemic mastocytosis (SM), is characterized by leukemic expansion of immature mast cells (MCs) in the…”
Get full text

Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria by Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin-Nelemans, H. C., Hamdy, N. A. T., Lortholary, O., Robyn, J., Van Doormaal, J., Sotlar, K., Hauswirth, A. W., Arock, M., Hermine, O., Hellmann, A., Triggiani, M., Niedoszytko, M., Schwartz, L. B., Orfao, A., Horny, H.-P., Metcalfe, D. D.

“…Although a classification for mastocytosis and diagnostic criteria are available, there remains a need to define standards for the application of diagnostic…”
Get full text

BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils by Smiljkovic, D., Blatt, K., Stefanzl, G., Dorofeeva, Y., Skrabs, C., Focke‐Tejkl, M., Sperr, W. R., Jaeger, U., Valenta, R., Valent, P.

“…Background Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)‐cross‐linked basophils. Methods We…”
Get full text

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders by Valent, P, Sotlar, K, Blatt, K, Hartmann, K, Reiter, A, Sadovnik, I, Sperr, W R, Bettelheim, P, Akin, C, Bauer, K, George, T I, Hadzijusufovic, E, Wolf, D, Gotlib, J, Mahon, F-X, Metcalfe, D D, Horny, H-P, Arock, M

“…Basophils form a distinct cell lineage within the hematopoietic cell family. In various myeloid neoplasms, including chronic myeloid leukemia, basophilia is…”
Get full text

Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells by Gschwandtner, M., Paulitschke, V., Mildner, M., Brunner, P. M., Hacker, S., Eisenwort, G., Sperr, W. R., Valent, P., Gerner, C., Tschachler, E.

“…Background The function of skin mast cells has been well documented in IgE‐mediated allergic reactions, whereas other mast cell functions are poorly defined…”
Get full text

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group by Sperr, W. R., Wimazal, F., Kundi, M., Baumgartner, C., Nösslinger, T., Makrai, A., Stauder, R., Krieger, O., Pfeilstöcker, M., Valent, P.

“…Background: The evaluation of comorbidity is of increasing importance in patients with hematologic disorders. Patients and methods: In the present study, the…”
Get full text

Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study by Zeilinger, E. L., Oppenauer, C., Knefel, M., Kantor, V., Schneckenreiter, C., Lubowitzki, S., Krammer, K., Popinger, C., Kitta, A., Kum, L., Adamidis, F., Unseld, M., Masel, E. K., Füreder, T., Zöchbauer-Müller, S., Bartsch, R., Raderer, M., Prager, G., Krauth, M. T., Sperr, W. R., Porpaczy, E., Staber, P. B., Valent, P., Gaiger, A.

“…Abstract Aims Cancer patients often present with psychological symptoms that affect their quality of life, physical health outcomes and survival. Two of the…”
Get full text

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease by Hoermann, G., Gleixner, K. V., Dinu, G. E., Kundi, M., Greiner, G., Wimazal, F., Hadzijusufovic, E., Mitterbauer, G., Mannhalter, C., Valent, P., Sperr, W. R.

“…KIT D816V is present in a majority of patients with systemic mastocytosis (SM). We determined the KIT D816V allele burden by quantitative real‐time PCR in bone…”
Get full text

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies by Mothes, N., Heinzkill, M., Drachenberg, K. J., Sperr, W. R., Krauth, M. T., Majlesi, Y., Semper, H., Valent, P., Niederberger, V., Kraft, D., Valenta, R.

“…Summary Background Allergen‐specific immunotherapy represents a causal form of treatment for IgE‐mediated allergies. The allergen extract‐based analyses of…”
Get full text

Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge by Horny, H-P, Sotlar, K, Sperr, W R, Valent, P

“…Aims: Although systemic mastocytosis (SM) with an associated clonal haematological non-mast cell lineage disease (SM-AHNMD) is a major subtype of SM, little is…”
Get full text

Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology by Sperr, W. R., El-Samahi, A., Kundi, M., Girschikofsky, M., Winkler, S., Lutz, D., Endler, G., Rumpold, H., Agis, H., Sillaber, C., Jäger, U., Valent, P.

“…Background  Recent data suggest that tryptase, a mast cell enzyme, is expressed in neoplastic cells in myeloid leukaemias. In several of these patients,…”
Get full text

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes by Nösslinger, T., Tüchler, H., Germing, U., Sperr, W. R., Krieger, O., Haase, D., Lübbert, M., Stauder, R., Giagounidis, A., Valent, P., Pfeilstöcker, M.

“…Background: The International Prognostic Scoring System (IPSS) is the golden standard to assess prognosis in myelodysplastic syndromes (MDS). The aim of this…”
Get full text

Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination by Focke, M., Linhart, B., Hartl, A., Wiedermann, U., Sperr, W. R., Valent, P., Thalhamer, J., Kraft, D., Valenta, R.

“…Summary Background Almost 100 million allergic patients are sensitized to the major birch pollen allergen, Bet v 1, a 17 kDa protein containing most of the IgE…”
Get full text

Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia by Preuner, S, Mitterbauer, G, Mannhalter, C, Herndlhofer, S, Sperr, W.R, Valent, P, Lion, T

“…Abstract Background In chronic myeloid leukaemia (CML), clonal evolution with resistance to tyrosine kinase inhibitors (TKIs) is often triggered by BCR/ABL1…”
Get full text

Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells by Hauswirth, A.W., Florian, S., Printz, D., Sotlar, K., Krauth, M.-T., Fritsch, G., Schernthaner, G.-H., Wacheck, V., Selzer, E., Sperr, W.R., Valent, P.

“…Background  CD33 (Siglec‐3) is becoming increasingly important as a target of antibody‐mediated therapy in acute myeloid leukaemia (AML). In normal…”
Get full text

Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis by Aichberger, K. J., Sperr, W. R., Gleixner, K. V., Kretschmer, A., Valent, P.

“…ABSTRACT Background  Systemic mastocytosis (SM) is a mast cell neoplasm in which neoplastic cells usually display the D816V‐mutated variant of KIT. Cladribine…”
Get full text

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia by Sillaber, C., Mayerhofer, M., Böhm, A., Vales, A., Gruze, A., Aichberger, K. J., Esterbauer, H., Pfeilstöcker, M., Sperr, W. R., Pickl, W. F., Haas, O. A., Valent, P.

“…ABSTRACT Background  Recent data suggest that the mammalian target of rapamycin (mTOR) is involved in the regulation of growth of neoplastic cells in chronic…”
Get full text

Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin by Bugajska-Schretter, A, Grote, M, Vangelista, L, Valent, P, Sperr, W R, Rumpold, H, Pastore, A, Reichelt, R, Valenta, R, Spitzauer, S

“…BACKGROUND Almost 4% of the population suffer from food allergy which is an adverse reaction to food with an underlying immunological mechanism. AIMS To…”
Get full text

Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes by Wimazal, F., Sperr, W. R., Kundi, M., Vales, A., Fonatsch, C., Thalhammer-Scherrer, R., Schwarzinger, I., Valent, P.

“…Background: Early recognition of disease progression in low-risk myelodysplastic syndromes (MDS) is an important decision point concerning intensive therapies…”
Get full text